Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Hodgkin's Lymphoma (HL) Opportunity Analysis and Forecasts to 2024 - Adcetris to Retain and Extend its Lead as the $1.4 Billion HL Market Front-Runner - Research and Markets

Research and Markets
Posted on: 10 Oct 16

Research and Markets has announced the addition of the "Opportunity Analyzer: Hodgkin's Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024" drug pipelines to their offering.

Hodgkin's lymphoma (HL), or Hodgkin's disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good.

However, treatment options for those patients who have failed first-line treatment are very few, and a significant unmet medical need remains in those patients. Estimated HL market in the 7MM was valued at $316m in 2014. The HL market will increase approximately four-fold over the forecast period, reaching $1.4 billion by 2024 at a CAGR of 16%.

This growth will be driven by label extensions for Adcetris (brentuximab vedotin), which is poised to enter earlier lines of HL therapy, as well as the approval and uptake of premium-priced products, such as the immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab).

Adcetris to retain and extend its lead as the HL market front-runner, with Opdivo and Keytruda making up a significant amount of the market.

Key Findings

  • One of the main drivers in the expansion of the HL market will be the label extensions of Adcetris in earlier lines of HL therapy, which will include the post-transplantation consolidation setting, as well as newly diagnosed advanced stage patients. The premium-priced anti-PD1-therapies, Opdivo and Keytruda, will also launch and be used in the treatment of the R/R HL population. These drugs are poised to partially meet the remaining unmet medical need of these hard-to-treat patients.
  • Another driver of market growth will be the few players in the HL space; therefore, there is ample room for new market entrants. A major driver will also be an increase in HL incidence due to a growing population. This will lead to an overall increase of the number of drug-treatable HL patients, and market size.
  • Companies are focusing on the development of therapies targeting the R/R HL population, hoping to expedite the route to market for their pipeline products, and improving the complete remission rate and duration of remission of these patients.
  • One of the largest unmet needs is that of the newly diagnosed advanced stage HL population. Other unmet needs include the high proportion of patients failing transplant therapies and the toxicity of second-line treatment options.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Current Treatment Options

6 Unmet Needs Assessment and Opportunity Analysis

7 R&D Strategies

8 Pipeline Assessment

9 Pipeline Valuation Analysis

10 Appendix

Companies Mentioned

  • 4SC
  • Acetylon Pharmaceuticals
  • Actinium Pharmaceuticals
  • ADC Therapeutics
  • Affimed Therapeutics
  • Amgen
  • Aptose Biosciences
  • Bayer Schering Pharma
  • Bellicum Pharmaceuticals
  • Bristol-Myers Squibb
  • Cell Medica Limited
  • Cellular Biomedicine Group
  • Constellation Pharmaceuticals
  • Curis
  • Eddingpharm
  • Gamida Cell
  • Incyte Corporation
  • Johnson & Johnson
  • Kyowa Hakki Kirin
  • Linus Oncology
  • Medarex
  • Menarini
  • Merck & Co.
  • Millennium Pharmaceuticals
  • Mirati Therapeutics
  • NantKwest
  • Novartis
  • Ono Pharmaceutical
  • Pfizer
  • Seattle Genetics
  • Syndax Pharmaceuticals
  • Takeda
  • Teva
  • TG Therapeutics
  • Yakult Honsha

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/h55qmx/opportunityanalyze

View source version on businesswire.com: http://www.businesswire.com/news/home/20161010005791/en/

Business Wire
www.businesswire.com

Last updated on: 10/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.